|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-1-23
|
|
pubmed:abstractText |
Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
pubmed-author:BonkovskyHerbert LHL,
pubmed-author:Di BisceglieAdrian MAM,
pubmed-author:DienstagJules LJL,
pubmed-author:EversonGregory TGT,
pubmed-author:GhanyMarc GMG,
pubmed-author:GretchDavid RDR,
pubmed-author:LeeWilliam MWM,
pubmed-author:LindsayKaren LKL,
pubmed-author:LokAnna S FAS,
pubmed-author:MorganTimothy RTR,
pubmed-author:ShiffmanMitchell LML,
pubmed-author:WrightElizabeth CEC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
103-12
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17241864-Adolescent,
pubmed-meshheading:17241864-Adult,
pubmed-meshheading:17241864-Aged,
pubmed-meshheading:17241864-Aged, 80 and over,
pubmed-meshheading:17241864-Antiviral Agents,
pubmed-meshheading:17241864-Body Weight,
pubmed-meshheading:17241864-Drug Therapy, Combination,
pubmed-meshheading:17241864-Female,
pubmed-meshheading:17241864-Genotype,
pubmed-meshheading:17241864-Hepacivirus,
pubmed-meshheading:17241864-Hepatitis C, Chronic,
pubmed-meshheading:17241864-Humans,
pubmed-meshheading:17241864-Interferon-alpha,
pubmed-meshheading:17241864-Liver Cirrhosis,
pubmed-meshheading:17241864-Male,
pubmed-meshheading:17241864-Middle Aged,
pubmed-meshheading:17241864-Polyethylene Glycols,
pubmed-meshheading:17241864-Prospective Studies,
pubmed-meshheading:17241864-Recombinant Proteins,
pubmed-meshheading:17241864-Recurrence,
pubmed-meshheading:17241864-Ribavirin,
pubmed-meshheading:17241864-Time Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
|
|
pubmed:affiliation |
Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA. mshiffma@vcu.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
